Bone Biologics (Bone Biologics) Short-Term Debt : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bone Biologics Short-Term Debt?

Bone Biologics's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

Bone Biologics Short-Term Debt Historical Data

The historical data trend for Bone Biologics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bone Biologics Short-Term Debt Chart

Bone Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

11.72

Bone Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Bone Biologics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Bone Biologics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Bone Biologics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bone Biologics (Bone Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLGW) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

BBLG:USA

Address

2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803

Website

https://www.bonebiologics.com

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.